Tevimbra™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Oesophageal squamous cell carcinoma (OSCC),TEVIMBRA in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma with a PD-L1 expression equal to or greater than 1%.,TEVIMBRA as monotherapy is indicated for the treatment of adult patients with unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy.,Non-small cell lung cancer (NSCLC),TEVIMBRA in combination with pemetrexed and platinum containing chemotherapy is indicated for the first-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), with PD-L1 expression equal to or greater than 50% but no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.,TEVIMBRA in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.,TEVIMBRA as monotherapy is indicated for the treatment of patients with locally advanced or metastatic NSCLC after prior chemotherapy.,Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma,TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (G/GOJ) adenocarcinoma with a PD-L1 expression equal to or greater than 1%.,Nasopharyngeal carcinoma (NPC),TEVIMBRA in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze; Refrigerate; Do not Shake

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, concentrated
• Intravenous Infusion
• Clear to slightly opalescent, colorless to slightly yellow solution.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 x carton containing 1 x single-dose vial

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item codes 14756P (Opens in new tab) and 14765D (Opens in new tab). Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Tislelizumab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).